Preclinical Imaging Market to Grow with a CAGR of 4.45% through 2028
Increase in the drug development and increase in
institutional research is expected to drive the Global Preclinical Imaging
Market growth in the forecast period, 2024-2028.
According to
TechSci Research report, “Preclinical Imaging Market – Global Industry Size,
Share, Trends, Competition Forecast & Opportunities, 2028”, the
Global Preclinical Imaging Market stood at USD 3.94 billion in 2022 and is
anticipated to grow with a CAGR of 4.45% in the forecast period, 2024-2028. The
awareness among individuals regarding Preclinical Imaging has led to favorable
market conditions for the global Preclinical Imaging market. Several factors
contribute to the growth of various Preclinical Imaging products.
The
pharmaceutical and biotechnology sectors are among the most significant
consumers of preclinical imaging technologies. These industries rely on
preclinical imaging to expedite drug development processes. By assessing drug
efficacy and safety in preclinical stages, companies can make informed
decisions about candidate compounds, ultimately reducing the time and cost of
bringing new therapies to market. The growing trend toward personalized
medicine is another key driver. Preclinical imaging plays a pivotal role in
tailoring treatments to individual patients based on their unique molecular
profiles.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Preclinical Imaging Market”
Preclinical
imaging bridges the gap between laboratory discoveries and clinical
applications, facilitating translational research. It allows scientists to
validate hypotheses, study the feasibility of new treatments, and assess safety
and efficacy before advancing to human trials. This reduces the risk associated
with clinical trials and expedites the delivery of therapies to patients. The
world faces ever-evolving health challenges, from emerging infectious diseases
to the rising burden of chronic conditions. Preclinical imaging equips
researchers with the tools to explore new avenues of diagnosis and treatment,
offering hope in the face of these global health crises, which will further
fuel market growth.
In July 2023, GE
Healthcare launched a new PET/CT system called Discovery IQ. This system is
designed for high-throughput imaging of small animals, and it can be used to
image a wide range of diseases, including cancer and neurodegenerative diseases.
Technological
advancements have also led to the integration of multiple imaging modalities
into a single platform. This approach, known as multi-modal imaging, combines
the strengths of different techniques to provide a more comprehensive view of
biological processes. Researchers can simultaneously capture anatomical,
functional, and molecular information, enhancing the quality and depth of their
research, and growing awareness of the importance of Preclinical Imaging are
expected to positively impact the global Preclinical Imaging market.
In today's
fast-paced world, Imaging helps determine whether a drug candidate is effective
in animal models, allowing for swift decision-making on whether to proceed to
clinical trials.
preclinical
imaging tracks the effects of drugs over time, ensuring their safety and
efficacy in a time-efficient manner. Early identification of potential issues
through imaging reduces the likelihood of costly late-stage drug failures. The
world of healthcare is shifting towards personalized medicine, where treatments
are tailored to individual patients. Preclinical imaging contributes by:
Imaging enables
the creation of animal models that replicate an individual patient's disease
and response to treatment, guiding the development of personalized therapies. By
studying disease models and potential treatment outcomes in advance,
preclinical imaging aids in optimizing treatment plans, reducing trial and
error in patient care.
Global health
challenges, such as pandemics and emerging infectious diseases, demand swift
responses. Real-time monitoring of pathogens in animal models through imaging
helps researchers understand disease progression and develop interventions more
rapidly. Imaging plays a key role in assessing the effectiveness of vaccines
and treatments against infectious diseases, expediting the development of vital
interventions.
The growth of
academic and research institutions dedicated to life sciences is driving the
demand for preclinical imaging systems and expertise. As more institutions
invest in cutting-edge imaging facilities, it creates a ripple effect,
propelling the entire industry forward.
In recent years,
preclinical imaging has become an indispensable tool in the fields of
biomedical research, drug development, and personalized medicine. Its
non-invasive and high-resolution imaging capabilities have revolutionized the
way scientists study and understand biological processes, diseases, and the
effects of potential treatments. Consequently, Preclinical imaging plays a
pivotal role in cancer research by allowing scientists to detect, monitor, and
characterize tumors in animal models. Imaging techniques such as positron
emission tomography (PET) and magnetic resonance imaging (MRI) provide valuable
insights into tumor size, location, metabolism, and response to treatments.
However, the Cost of Technology and Infrastructure may hinder market growth.
Moreover, challenges related to regulatory and ethical considerations may pose
obstacles to the vitamins market in the near future.
The Global Preclinical
Imaging Market is segmented into modality, and company.
Based on its
formulation, the optical imaging systems segment emerged as the dominant player
in the global market for Preclinical Imaging in 2022. Optical imaging systems
encompass a broad range of techniques, including bioluminescence imaging and
fluorescence imaging. This versatility allows researchers to study diverse
biological processes, from gene expression to protein-protein interactions.
Such flexibility is highly attractive in preclinical research, where a
multifaceted approach is often required.
Optical imaging
systems are relatively cost-effective compared to some other modalities like
magnetic resonance imaging (MRI) or positron emission tomography (PET). This
affordability factor makes optical imaging accessible to a wide range of
research institutions, from academic labs to smaller biotechnology companies.
Optical imaging
techniques are inherently non-invasive. They involve the use of light or
bioluminescent signals to capture images without the need for contrast agents
or ionizing radiation. This non-invasive nature minimizes harm to research
subjects, making optical imaging an ethical choice. Optical imaging allows for
real-time monitoring of biological processes. Researchers can track the
progression of diseases, observe drug responses, and study dynamic events such
as cell migration or tumor growth in live animals. This real-time capability
provides invaluable insights for preclinical studies. Optical imaging systems
excel at molecular imaging.
Based on region,
North America is home to a robust pharmaceutical and biotechnology industry.
Major players in these sectors continually invest in preclinical imaging to
accelerate drug development, contributing to the market's dominance. North
America has well-defined regulatory frameworks that support the use of
preclinical imaging in drug development. The U.S. Food and Drug Administration
(FDA) provides clear guidance on incorporating imaging data into regulatory
submissions, further bolstering the market. The region sees continuous
advancements in preclinical imaging technology. Innovations in modalities like
magnetic resonance imaging (MRI) and positron emission tomography (PET) are
commonplace, attracting researchers and industry stakeholders.
The
Asia-Pacific region, led by countries like China, Japan, and India, is
witnessing a surge in investment in research and development (R&D).
Governments and private sectors are allocating resources to advance biomedical
research, creating opportunities for preclinical imaging. The pharmaceutical
market in Asia-Pacific is expanding rapidly. With a growing population and
rising healthcare needs, there is a substantial demand for preclinical imaging
to support drug discovery and development. Many
global pharmaceutical companies are establishing collaborations and
partnerships with research institutions and contract research organizations
(CROs) in Asia-Pacific. These collaborations drive the adoption of preclinical
imaging technologies in the region. Countries like China are investing
heavily in healthcare infrastructure, including state-of-the-art research
facilities and hospitals. This investment includes the acquisition of advanced
imaging equipment. Regulatory bodies in Asia-Pacific countries are making
efforts to streamline regulations related to preclinical imaging.
Major companies
operating in Global Preclinical Imaging Market are:
- Aspect Imaging Ltd
- Bruker Corporation
- Fujifilm Holdings
Corporation
- Mediso Ltd
- MR Solutions Ltd
- PerkinElmer Inc.
- United Imaging
Healthcare Co. Ltd
- AXT PTY LTD
- Advanced Molecular
Vision, Inc.
- IVIM Technology
Corp
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“The advancement
in the technology and increasing Pharmaceutical and Biotechnology Sectors are
key drivers of the preclinical imaging market. In recent years, Traditional
techniques have been refined, and new, groundbreaking methods have emerged. For
instance, high-resolution micro-computed tomography (micro-CT) has enabled
researchers to explore the finest details of anatomical structures in small
animals. Moreover, the growing consumer emphasis on preventative healthcare
products has enhanced production and marketing efforts. To meet the demands of
the market, manufacturers are increasingly incorporating cutting-edge
technologies with high production efficiency. Rising consumer acceptance and
continuous product innovation will further ensure the growth of the vitamins
and supplements market in the coming years.,” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Preclinical
Imaging Market – Global Industry Size, Share, Trends, Opportunity &
Forecast 2018-2028 Segmented By Modality (Optical Imaging Systems, Nuclear
Imaging Systems, Micro-MRI, Micro-ultrasound, Micro-CT, Photoacoustic Imaging
Systems, Other), By Region, Competition”, has evaluated
the future growth potential of Global Preclinical Imaging Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Preclinical Imaging Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com